New therapeutic strategy: P2X7 and SIRT6
The post-doc will verify the efficacy and mechanism of action of inhibitors of two new therapeutic targets (P2X7 and SIRT6), in different models of diseases. Both the P2X7 receptor and the enzyme SIRT6 play an important role in inflammation.
The therapeutic efficacy of P2X7 inhibition will be evaluated in a murine model of muscle dystrophy (LGMD2D), an inherited disorder characterized by skeletal muscle degeneration and premature death. This pathology is worsened by inflammatory processes. Moreover, the effects of extracellular ATP, the P2X7 agonist, will be characterized on myoblasts isolated from patients with LGMD2D.
Moreover, a number of SIRT6 inhibitors will be optimized and tested on models of pathologies with an inflammatory component.
This job comes from a partnership with Science Magazine and